Neurosurgical patients constitute a moderate risk group for development of deep venous thrombosis and pulmonary thromboembolism. In untreated neurosurgical patients, incidence of DVT is reported to be between 18% and 50%. Incidence of PE in neurosurgical patients varies between 8% and 25%. Mechanical prophylaxis reduces the risk of DVT by 10–20%.2,3 VTE after spine surgery varies between 8.3% and 19% with symptomatic PE in only 0.2% patients. The large variation in incidence reported is due to the heterogeneity in the method of diagnosis, inclusion of symptomatic or asymptomatic patients, and whether receiving any prophylaxis or not. While PE is the most commonly recognized in hospital consequence of DVT, venous incompetence and postthrombotic syndrome are a recognized source of morbidity in patients with a history of DVT. Postthrombotic syndrome is estimated to affect 23–60% of patients with DVT. Neurological surgery is well suited for the incorporation of robotic assistance. Bony superstructure meant small holes for manipulation—spurring a growth in stereotactic surgery. This minimally invasive neurosurgery became possible once CT scans allowed for pinpoint localization of lesions. Fortunately, NSCs are excellent candidates based on their ability to track cancer cells, capacity to be genetically modified, and, if proven to be the cell of origin, could even be targeted in a pre-morbid state.